EMR trades against a final fair-value range of $88.69-$155.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $88.7, high $156, with mid-point at $122.
Currently screens above fair value, so patience matters more than entry speed.
Fair value
$122
Margin of safety
-12.3%
Confidence
87/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$137.28Price
Low $88.69
Mid $122.21
High $155.92
EMR trades against a final fair-value range of $88.69-$155.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
High switching costs associated with
High switching costs associated with mission-critical process automation platforms like DeltaV.
Sticky, high-margin software and service
Sticky, high-margin software and service recurring revenue base.
Bull thesis
Reduce-side internal valuation cross-checks ($164.87) aggressively prices in perfect execution of the M&A synergy playbook and permanent retention of 24.2% outlier margins.
Our financial-history view of EMR (EMR) covers revenue, gross profit, operating income, and net income across the past five fiscal years, with year-over-year growth and margin context for each line.
The revenue trajectory is reported in the financial-history section with year-over-year growth rates. Direction and acceleration are summarised inline; the full table sits within the parent financials tab.
We track operating income alongside operating margin so the reader can separate top-line growth from operating leverage. The numbers analysis subsection flags one-offs, restructuring, and stock-based-compensation effects when material.
Net income is shown together with EPS so dilution and buybacks are visible alongside profit. Where reported net income diverges materially from operating cash flow, the discrepancy is called out in the numbers-analysis subsection.
FAQ
EMR — frequently asked questions
Based on our latest analysis, EMR screens modestly overvalued. The current price is $137 versus a composite fair-value midpoint of $122 (range $88.7–$156), which implies roughly 11.0% downside to the midpoint.
Our composite fair-value range for EMR is $88.7–$156, with a midpoint of $122. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for EMR's archetype.
Our current rating for EMR is Reduce with a confidence score of 87/100. EMR is rated Reduce at $137.28 versus the reconciled fair value midpoint of $122.21, implying -10.98% upside/downside. Confidence is separately disclosed at 87/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for EMR are: M&A Value Destruction; Automation CAPEX Freeze; Margin Reversion. The single biggest risk is M&A Value Destruction: Failure to extract synergies from recent software acquisitions causes ROIC to stagnate below WACC, driven by the $18B goodwill burden.
Our current rating for EMR is Reduce, issued with a confidence score of 87/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($88.7–$156) versus the current price of $137.
EMR is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for EMR.
